Article

Do infants increase the risk of re-emergent infection in households after mass drug administration for trachoma?

Dana Center for Preventive Ophthalmology, Wilmer Eye Institute, Johns Hopkins University, Baltimore, Maryland 21287-9019, USA.
Investigative ophthalmology & visual science (Impact Factor: 3.43). 06/2011; 52(8):6040-2. DOI: 10.1167/iovs.11-7372
Source: PubMed

ABSTRACT Mass treatment with azithromycin for trachoma endemic communities typically excludes infants under age 6 months, whose parents are provided with tubes of tetracycline to administer daily over 4 to 6 weeks. The authors sought to determine whether infants aged <6 months are a source of re-emergent infection in their families after mass treatment in trachoma-endemic communities.
In a longitudinal study of all children aged less than 10 years in four communities, the authors identified 91 infants aged <6 months living in 86 of 1241 households. All children aged <ten years in all households were examined for trachoma and ocular infection with C. trachomatis at baseline, and 6 months after mass drug administration.
The prevalence of infection at baseline in the infants was 5.9%. At 6 months post mass drug administration, the rate of infection among children older than 6 months and less than 10 years who resided in households with infants was 6.0% compared with 11.1% in children in households without infants (P = 0.18). After adjustment for age, sex, baseline infection status, and treatment, residing in a household with an infant was not associated with infection at 6 months (odds ratio [95% confidence interval] 0.50 [0.20-1.22]).
This prospective study did not find evidence that living in a household with an infant increased the risk of infection 6 months post mass drug administration in other children residing in the household.

0 Bookmarks
 · 
81 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Trachoma, the leading infectious cause of blindness, is a chronic conjunctivitis caused by repeated reinfections with Chlamydia trachomatis. Trachoma is a disease of entire communities, with the reservoir of infection residing in children, especially preschool children. The World Health Assembly has targeted the year 2020 for the elimination of blinding trachoma as a public health problem, and mass treatment with antibiotics is part of the multifaceted SAFE strategy recommended for country programs. Tanzania was one of the first countries to be the recipient of azithromycin for use in mass distribution programs and has been the site of a continuous research effort on trachoma control in the Kongwa district, the Kongwa Trachoma Project, since 1986. The authors discuss some events leading up to the use of azithromycin for trachoma, our experiences and lessons learned with use of azithromycin, intervention goals, achieving high coverage and the challenges to achieving elimination by 2020.
    Expert Review of Ophthalmology 01/2014; 8(3).
  • [Show abstract] [Hide abstract]
    ABSTRACT: To review recent clinical and epidemiological studies regarding the prevention, diagnosis, and treatment of trachoma. Newer studies propose novel diagnostic tests that appear sensitive for the detection of ocular chlamydial infection. For example, recent studies with ribosomal RNA-based nucleic acid amplification tests (NAATs) have demonstrated improved sensitivities compared to DNA-based NAATs; and the progression of scarring has now been characterized with confocal microscopy. Immunologic studies have further explored the etiology of clinical sequelae, suggesting that chronic inflammation can lead to progressive scarring even in the absence of Chlamydia. Mass oral azithromycin distributions remain a mainstay of treatment; studies have assessed the appropriate frequency and duration of treatment programs. Current studies have also explored ancillary effects of azithromycin distribution on mortality and bacterial infections. Trachoma programs have had remarkable success at reducing chlamydial infection and clinical signs of trachoma. Recent work suggests improved methods to monitor infection and scarring, and better ways to distribute treatment. Whereas studies continue to demonstrate reduction in infection in hyperendemic areas, more work is necessary to achieve elimination of this blinding disease.
    Current opinion in ophthalmology 05/2012; 23(4):288-95. · 2.49 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Trachoma, a chronic conjunctivitis caused by Chlamydia trachomatis, is the leading infectious cause of blindness worldwide. In recognition of this public health problem, the World Health Assembly has targeted the year 2020 to eliminate blinding trachoma, and a multifaceted strategy (SAFE) is recommended, including antibiotics for treatment of infection. Trachoma is a disease of entire communities, and the pool of infection resides largely in preschool age children. Thus, for endemic communities, mass treatment with antibiotics annually for at least 3-5 years is carried out. The antibiotics used, the effectiveness of this approach, and the challenges of antibiotic treatment of communities are discussed, concluding with a view towards the elimination of trachoma in the future.
    Expert Review of Anticancer Therapy 01/2012; 10(1):75-83. · 3.22 Impact Factor

Full-text (2 Sources)

Download
6 Downloads
Available from
May 29, 2014